6610 Stock Overview
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TWi Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$11.60 |
| 52 Week High | NT$23.00 |
| 52 Week Low | NT$11.60 |
| Beta | 0.54 |
| 1 Month Change | -13.43% |
| 3 Month Change | -9.02% |
| 1 Year Change | -48.44% |
| 3 Year Change | -49.57% |
| 5 Year Change | -41.91% |
| Change since IPO | -82.90% |
Recent News & Updates
Shareholder Returns
| 6610 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -11.5% | -4.2% | -3.7% |
| 1Y | -48.4% | -25.6% | 24.4% |
Return vs Industry: 6610 underperformed the TW Biotechs industry which returned -25.6% over the past year.
Return vs Market: 6610 underperformed the TW Market which returned 24.4% over the past year.
Price Volatility
| 6610 volatility | |
|---|---|
| 6610 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 4.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6610 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6610's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 19 | Jessica Wu | www.twibiotech.com |
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited.
TWi Biotechnology, Inc. Fundamentals Summary
| 6610 fundamental statistics | |
|---|---|
| Market cap | NT$1.02b |
| Earnings (TTM) | -NT$78.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.0x
P/E RatioIs 6610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6610 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$78.05m |
| Earnings | -NT$78.04m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6610 perform over the long term?
See historical performance and comparison